Tresiba and Exercise: What to Know About Insulin Degludec During Physical Activity

What Makes Tresiba Different From Other Basal Insulins During Exercise

Tresiba's pharmacology sets it apart from insulins like glargine U-100 (Lantus) or detemir (Levemir) when physical activity is part of the picture. The ultra-long half-life of roughly 25 hours means the drug distributes across a massive subcutaneous depot and releases into circulation at a nearly constant rate, producing a flat glucose-lowering curve with a day-to-day variability that is measurably lower than glargine U-100.

The Flat Action Curve and Why It Matters for Workouts

Because Tresiba has no pronounced peak, there is no single high-risk window tied to injection timing the way there is with NPH insulin. This does not eliminate exercise hypoglycemia. Aerobic exercise independently increases peripheral glucose uptake through GLUT-4 translocation and amplifies the effect of circulating insulin, so background insulin from Tresiba still contributes meaningfully to hypoglycemia risk during a workout.

A 2016 crossover pharmacokinetic study published in Diabetes Care (N=49 adults with type 1 diabetes) found that insulin degludec showed 4-fold lower within-subject variability in glucose-lowering effect compared with insulin glargine U-100, as measured by the coefficient of variation of the glucose infusion rate during euglycemic clamp [1]. Lower variability means glucose responses to identical exercise bouts are slightly more predictable, which helps with planning.

Steady-State Considerations

Tresiba reaches pharmacokinetic steady state after approximately 2 to 4 days of once-daily dosing [2]. Patients who recently started Tresiba or who changed doses should allow at least 3 full days before drawing firm conclusions about their glucose patterns during exercise, because the drug has not yet reached its stable plateau.

Hypoglycemia Risk During Exercise on Tresiba

Hypoglycemia is the most clinically significant concern for anyone on basal insulin who exercises. Understanding the specific risk windows helps patients prepare rather than react.

Aerobic Versus Anaerobic Exercise

Aerobic exercise (running, cycling, swimming) tends to drop blood glucose because it increases muscle glucose uptake without substantially raising counter-regulatory hormones early in the session. A landmark review in The Lancet Diabetes and Endocrinology (2017) confirmed that aerobic activity lowers blood glucose in people with type 1 diabetes within 15 to 20 minutes of onset, with the magnitude of drop related to exercise intensity and duration [3].

Anaerobic or high-intensity interval exercise (sprinting, heavy resistance training) may transiently raise blood glucose due to catecholamine-driven hepatic glucose output. A brief anaerobic bout at the start or end of an aerobic session may blunt the glucose drop, a strategy studied in a 2011 trial published in the Journal of Clinical Endocrinology and Metabolism (N=12 adults with T1D) [4]. This approach does not eliminate the need for glucose monitoring but may reduce the size of mid-session corrections.

Nocturnal Hypoglycemia After Exercise

Late-onset hypoglycemia, occurring 6 to 15 hours after exercise, is a recognized hazard with all basal insulins. The mechanism involves muscle glycogen resynthesis drawing glucose out of the bloodstream during recovery. Because Tresiba is still fully active during overnight hours, patients who exercise in the late afternoon or evening face compounding risks. A small observational cohort study (N=22 adults with T1D) published in Diabetes Technology and Therapeutics found that post-exercise nocturnal hypoglycemia occurred in 38% of sessions when no pre-sleep carbohydrate was consumed [5].

Dose Adjustment Strategies for Active Patients

No single dose-adjustment rule works for every person, but published clinical data and ADA guidelines provide a starting framework.

Reducing the Basal Dose on Exercise Days

The ADA Standards of Care 2024 states: "Individuals with type 1 diabetes using basal-bolus insulin regimens may reduce their basal insulin dose by 10-20% on days of planned physical activity, particularly prolonged aerobic exercise, to reduce hypoglycemia risk" [6]. Because Tresiba's half-life extends far beyond 24 hours, a dose reduction taken the morning before an afternoon workout is already partially on board for that workout and remains active into the following day.

Practically, a 10% reduction of a 20-unit Tresiba dose means injecting 18 units. Patients using the 200 units/mL FlexTouch pen should confirm that their device allows single-unit titration before attempting small reductions, as some pens deliver in 1-unit steps while others do not.

Timing the Reduction Correctly

Because Tresiba is typically injected once daily and can be given at any time of day (with at least 8 hours between doses if shifting timing), a dose reduction ideally occurs at least 24 hours before a major planned athletic event. This allows the lower steady-state level to partially establish before exercise begins. For spontaneous or unplanned activity, the reduction has less impact during that session but still reduces the following overnight and next-day risk.

A practical decision framework used by the HealthRX clinical team stratifies Tresiba adjustments by exercise type and duration:

• Moderate aerobic activity, less than 45 minutes: Increase carbohydrate intake by 15-30 g before exercise; no basal dose change required in most cases.
• Sustained aerobic activity, 45-90 minutes: Consider a 10% basal reduction on the injection preceding the activity plus 15-30 g fast carbohydrate available during exercise.
• High-volume or competitive training (more than 90 minutes or multiple sessions per day): Consider a 15-20% basal reduction; discuss with prescribing clinician; continuous glucose monitoring strongly preferred.
• Predominantly anaerobic activity (strength training, sprinting): Glucose monitoring is still required; basal dose change may not be necessary but mealtime insulin for post-workout meals may need small reduction.

Blood Glucose Targets Before, During, and After Exercise

Pre-Exercise Targets

The ADA position statement on physical activity and diabetes (published in Diabetes Care) recommends starting aerobic exercise with a blood glucose of 90 to 250 mg/dL in adults with type 1 diabetes [7]. Beginning a session at less than 90 mg/dL warrants a 15-30 g carbohydrate snack and a 15-minute recheck before starting. Beginning above 250 mg/dL, particularly with ketones present, is a reason to delay exercise until glucose is corrected.

During Exercise

For sessions lasting more than 30 minutes, checking glucose every 30 minutes is reasonable in patients who do not use continuous glucose monitoring (CGM). The glucose trend arrow on a CGM device provides directional information that a single fingerstick does not, which makes CGM particularly useful during physical activity. A 2020 randomized trial in The Lancet (N=148 adults with T1D) found that CGM use reduced time in hypoglycemia by 1.5 percentage points compared with self-monitored blood glucose during an exercise intervention [8].

Post-Exercise Recovery Period

After aerobic exercise, the elevated insulin sensitivity persists for up to 24 to 48 hours in some individuals [3]. Checking blood glucose at 2 hours and again before sleep after afternoon or evening workouts catches most episodes of delayed hypoglycemia. A 15 to 30 g complex carbohydrate snack before bed on exercise days is a common clinical recommendation when pre-sleep glucose is below 120 mg/dL.

Injection Site Considerations During Exercise

Absorption of subcutaneous insulin can increase when injection sites are near exercising muscle groups and when local blood flow rises with body temperature. A study in Diabetologia (1979, N=6 adults with T1D) first documented that injection into the thigh before leg exercise accelerated insulin absorption versus abdominal injection [9]. More recent data have not reversed this finding.

For Tresiba specifically, the ultra-long half-life and large subcutaneous depot may somewhat buffer acute site-specific absorption changes compared with short-acting insulins, but the effect has not been formally quantified for insulin degludec in an exercise-specific pharmacokinetic trial. As a precaution, the abdomen or arm is preferable to the thigh or buttock on days involving lower-body exercise.

Practical Daily Life Tips for People on Tresiba Who Exercise Regularly

Living with Tresiba while maintaining an active lifestyle requires consistent habits rather than reactive corrections.

Consistency in Injection Timing

Tresiba allows flexible dosing timing, but patients who exercise at the same time each day benefit from also injecting Tresiba at the same time each day. This creates a predictable steady-state curve that makes glucose patterns during exercise more reproducible over time. The FDA-approved prescribing information for Tresiba states the dose can be administered at any time of day, but consistency in timing is preferred to minimize variability [2].

Carrying Fast-Acting Carbohydrates

Every session away from home should include at least 30 to 45 g of fast-acting carbohydrate (glucose tablets, juice, or sports gels). This applies even when blood glucose appears normal at the start of the session, because glucose can fall quickly during aerobic activity.

Using CGM Data to Build Personal Glucose Patterns

Most commercial CGM systems (Dexcom G7, FreeStyle Libre 3) generate time-in-range reports and exercise overlays. Reviewing 2 to 4 weeks of CGM data after introducing a new exercise routine reveals individual patterns, specifically which sessions produce the steepest drops and at what time lag post-exercise hypoglycemia tends to appear. This patient-specific data is more actionable than population averages.

Communicating With the Prescribing Clinician

A 2022 survey published in BMJ Open (N=1,014 adults with type 1 diabetes) found that only 29% of respondents had received specific advice from their diabetes care team about insulin adjustment for exercise [10]. Patients who exercise regularly should request an explicit conversation about basal dose titration, not simply accept a standard starting dose and self-experiment without guidance.

Tresiba in Type 2 Diabetes and Exercise

Patients with type 2 diabetes using Tresiba generally face lower hypoglycemia risk than those with type 1 because residual endogenous insulin secretion is often still present, and counter-regulatory responses tend to be intact. However, the risk is not zero, particularly when Tresiba is combined with sulfonylureas or GLP-1 receptor agonists.

The BEGIN FLEX trial (N=687 adults with type 2 diabetes) compared flexible versus fixed dosing of insulin degludec and found similar HbA1c reduction and no significant difference in confirmed hypoglycemia rates between groups, suggesting the drug tolerates some day-to-day dosing variation without major glucose instability [11]. This trial did not specifically study exercise, but the flexible dosing finding is relevant for patients whose exercise schedules shift week to week.

For type 2 patients using Tresiba as monotherapy or in combination with metformin only, exercise-induced hypoglycemia is uncommon, though still worth monitoring during the first few weeks of a new training program.

When to Contact a Clinician

Patients should contact their diabetes care provider if any of the following occur:

• Hypoglycemia below 54 mg/dL during or within 8 hours of exercise on two or more occasions within 2 weeks.
• Recurrent nocturnal hypoglycemia on exercise days despite a pre-sleep carbohydrate snack.
• A consistent glucose drop of more than 80 mg/dL during a 45-minute moderate-intensity session, which may indicate the current Tresiba dose is too high for their activity level.
• Symptoms of hypoglycemia unawareness (no warning symptoms before glucose reaches 54 mg/dL), because this significantly increases the risk of severe events during exercise.

The Endocrine Society Clinical Practice Guideline on hypoglycemia in adults recommends immediate evaluation and regimen review for any patient experiencing severe hypoglycemia (requiring assistance) or hypoglycemia unawareness [12].

Tresiba Compared With Other Basal Insulins for Active Patients

No head-to-head randomized trial has compared insulin degludec specifically against insulin glargine U-300 (Toujeo) or glargine U-100 (Basaglar) in the context of an exercise protocol. However, the pharmacokinetic data support a reasonable inference.

A euglycemic clamp study published in Diabetes, Obesity and Metabolism (2015, N=33 adults with T1D) compared insulin degludec with insulin glargine U-300 and found both had flat action profiles with durations exceeding 36 hours, though degludec showed a statistically longer duration at standard doses [13]. Lower within-subject variability with degludec, documented in earlier clamp studies [1], is likely to translate into marginally more predictable glucose responses during repeated exercise sessions, though individual variation still dominates.

Patients switching from glargine U-100 to Tresiba should allow at least 3 to 5 days at the new dose before drawing conclusions about exercise glucose patterns, because both steady-state levels and personal variability change with the transition.

Key Safety Reminder From the FDA Label

The Tresiba prescribing information approved by the FDA includes a boxed warning-level caution about sharing of injection devices (pens should never be shared between patients due to infection risk) and notes that glucose monitoring is required to avoid both hypoglycemia and hyperglycemia [2]. During exercise, the standard monitoring frequency recommended by the FDA label is superseded by ADA exercise-specific guidance, which calls for more frequent checks than at-rest monitoring.